Shionogi Looks Beyond Crestor to HIV Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's leading HIV candidate, S-349572, is an integrase inhibitor that had the strongest efficacy ever reported for the class in a Phase IIa study.